Publicaciones en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (65)

2024

  1. ERK5 Interacts with Mitochondrial Glutaminase and Regulates Its Expression

    International Journal of Molecular Sciences, Vol. 25, Núm. 6

2023

  1. An amino acid transporter subunit as an antibody-drug conjugate target in colorectal cancer

    Journal of experimental & clinical cancer research : CR, Vol. 42, Núm. 1, pp. 200

  2. Chemical-proteomics Identify Peroxiredoxin-1 as an Actionable Target in Triple-negative Breast Cancer

    International Journal of Biological Sciences, Vol. 19, Núm. 6, pp. 1731-1747

  3. Considerations for the clinical development of immuno-oncology agents in cancer

    Frontiers in immunology, Vol. 14, pp. 1229575

  4. Etiopathogenic role of ERK5 signaling in sarcoma: prognostic and therapeutic implications

    Experimental and Molecular Medicine, Vol. 55, Núm. 6, pp. 1247-1257

2022

  1. ERK5 Is a Major Determinant of Chemical Sarcomagenesis: Implications in Human Pathology

    Cancers, Vol. 14, Núm. 14

  2. Inhibition of ERK5 Elicits Cellular Senescence in Melanoma via the Cyclin-Dependent Kinase Inhibitor p21

    Cancer Research, Vol. 82, Núm. 3, pp. 447-457

  3. Novel adcs and strategies to overcome resistance to anti-her2 adcs

    Cancers, Vol. 14, Núm. 1

  4. Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis

    Therapeutic Advances in Medical Oncology, Vol. 14

  5. Surfaceome analyses uncover CD98hc as an antibody drug-conjugate target in triple negative breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 41, Núm. 1

  6. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody-Drug Conjugates in Breast Cancer

    Cancer research, Vol. 82, Núm. 24, pp. 4670-4679

  7. Transcriptomic Mapping of Non-Small Cell Lung Cancer K-RAS p.G12C Mutated Tumors: Identification of Surfaceome Targets and Immunologic Correlates

    Frontiers in Immunology, Vol. 12

  8. mTOR Inhibition and T-DM1 in HER2-Positive Breast Cancer

    Molecular Cancer Research, Vol. 20, Núm. 7, pp. 1108-1121

2021

  1. Clinical, genetic and pharmacological data support targeting the MEK5/ERK5 module in lung cancer

    npj Precision Oncology, Vol. 5, Núm. 1

  2. In silico transcriptomic mapping of integrins and immune activation in Basal-like and HER2+ breast cancer

    Cellular Oncology, Vol. 44, Núm. 3, pp. 569-580

  3. MZ1 co-operates with trastuzumab in HER2 positive breast cancer

    Journal of Experimental and Clinical Cancer Research, Vol. 40, Núm. 1

  4. Preclinical and clinical characterization of fibroblast-derived neuregulin-1 on trastuzumab and pertuzumab activity in HER2-positive breast cancer

    Clinical Cancer Research, Vol. 27, Núm. 18, pp. 5096-5108

  5. Transcriptomic profiles of cd47 in breast tumors predict outcome and are associated with immune activation

    International Journal of Molecular Sciences, Vol. 22, Núm. 8

2020

  1. Breast cancer heterogeneity and response to novel therapeutics

    Cancers, Vol. 12, Núm. 11, pp. 1-16

  2. Genomic Signatures of Immune Activation Predict Outcome in Advanced Stages of Ovarian Cancer and Basal-Like Breast Tumors

    Frontiers in Oncology, Vol. 9